Jincheng Pharm(300233)2024-03-28 16:00Financial Performance - In 2023, the company's operating revenue reached ¥3,538,312,459.65, a slight increase of 0.93% compared to ¥3,505,716,962.18 in 2022[47]. - The net profit attributable to shareholders was ¥174,709,358.21, representing a decrease of 36.09% from ¥273,364,594.00 in 2022[47]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥158,182,714.58, down 40.12% from ¥264,176,652.65 in 2022[47]. - The net cash flow from operating activities significantly increased by 159.78% to ¥664,075,132.81 from ¥255,626,529.37 in 2022[47]. - The total assets at the end of 2023 amounted to ¥5,916,079,328.81, reflecting a 1.54% increase from ¥5,826,083,590.97 in 2022[47]. - The net assets attributable to shareholders increased by 2.96% to ¥3,714,133,643.74 from ¥3,607,438,065.73 in 2022[47]. - The basic earnings per share decreased by 36.62% to ¥0.45 from ¥0.71 in 2022[47]. - The diluted earnings per share also decreased by 36.62% to ¥0.45 from ¥0.71 in 2022[47]. - The weighted average return on net assets was 4.75%, down from 7.81% in 2022, a decrease of 3.06%[47]. - The company reported a total of ¥20,542,633.74 in government subsidies, an increase from ¥19,141,348.49 in 2022[47]. Innovation and R&D - The company has applied for several patents during the reporting period, indicating ongoing innovation efforts[2]. - The company is focusing on R&D with several patents filed in 2023, indicating a commitment to innovation and market expansion[89]. - The company has established research institutes to accelerate the development of terminal formulations, specialty raw materials, and high-end pharmaceutical intermediates[97]. - The company emphasizes a three-tiered R&D innovation system that integrates independent innovation, collaborative innovation, and investment innovation[97]. - The company is actively pursuing international certification for several products, including new drugs like chlorpheniramine and oseltamivir phosphate[63]. - The company is exploring new technologies and methods to enhance production efficiency and product quality, as shown by its recent patent filings[89]. Market Strategy and Expansion - The company focuses on four strategic development directions: Pharma-Chem, synthetic biology, Fem-Tech, and high-quality antibiotics, enhancing synergy across technology, market, operations, and management[59]. - The company aims to create a well-known brand in women's health technology, with key products including vaginal soft capsules and creams[63]. - The company is actively pursuing new strategies for market expansion and product development, as evidenced by its recent patent applications[89]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share within the next two years[155]. - A strategic acquisition of a local pharmaceutical company is in progress, which is expected to enhance the company's product portfolio and increase market competitiveness[155]. Environmental Compliance and Sustainability - The company has invested over CNY 190 million in environmental protection facilities and operations in 2023, with an environmental protection tax payment of CNY 166,700[168]. - The company reported a nitrogen oxide emission level of 5.33 mg/m³, which is below the standard limit of 10 mg/m³[136]. - The company achieved a COD discharge level of 80.3 mg/L, significantly lower than the B-level standard limit of 500 mg/L[136]. - The company has implemented a new wastewater discharge system that complies with the GB/T 31962-2015 standard[136]. - The company has a comprehensive environmental information disclosure system, including public display boards and online monitoring connections with local environmental authorities[198]. - The company is committed to sustainability, with plans to reduce carbon emissions by 20% over the next five years through various initiatives[155]. Corporate Governance - The company has established a governance structure to protect the rights of shareholders and creditors, ensuring effective checks and balances among the shareholders' meeting, board of directors, and management[199]. - The company’s financial report has been confirmed by its board members, ensuring the accuracy and completeness of the information presented[18]. - The company emphasizes the importance of risk awareness regarding future development statements, highlighting potential policy and market risks[7]. Production and Operations - The company has established nine production bases across multiple provinces, with a strong market share in cephalosporin intermediates and glutathione raw materials[114]. - The company has a production capacity ranging from milligram to ton levels, with total reaction volumes reaching up to 5000 cubic meters for both chemical synthesis and biological fermentation[117]. - The company has integrated automation and intelligent upgrades in production processes to enhance safety and efficiency[118]. - The company adheres to GMP standards in its production processes, ensuring compliance with annual operational goals and market demands[64].